117 related articles for article (PubMed ID: 38168630)
1. Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.
Terao M; Yamashita Y; Takada Y; Itoh Y; Suzuki T
Bioorg Med Chem; 2024 Jan; 98():117579. PubMed ID: 38168630
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
4. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
5. The KDM5 Inhibitor KDM5-C70 Induces Astrocyte Differentiation in Rat Neural Stem Cells.
Lee HR; Ann J; Kim YM; Lee J; Kim HJ
ACS Chem Neurosci; 2021 Feb; 12(3):441-446. PubMed ID: 33482060
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
7. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
8. At Long Last Potent and Selective KDM5 Inhibitors.
Rotili D; Mattevi A
Cell Chem Biol; 2016 Jul; 23(7):749-751. PubMed ID: 27447042
[TBL] [Abstract][Full Text] [Related]
9. Functions and Interactions of Mammalian KDM5 Demethylases.
Pavlenko E; Ruengeler T; Engel P; Poepsel S
Front Genet; 2022; 13():906662. PubMed ID: 35899196
[TBL] [Abstract][Full Text] [Related]
10. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
11. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
12. BRWD3 promotes KDM5 degradation to maintain H3K4 methylation levels.
Han D; Schaffner SH; Davies JP; Benton ML; Plate L; Nordman JT
Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2305092120. PubMed ID: 37722046
[TBL] [Abstract][Full Text] [Related]
13. KDM5 demethylases and their role in cancer cell chemoresistance.
Plch J; Hrabeta J; Eckschlager T
Int J Cancer; 2019 Jan; 144(2):221-231. PubMed ID: 30246379
[TBL] [Abstract][Full Text] [Related]
14. Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?
Ohguchi Y; Ohguchi H
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805040
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
16. Characterization of KDM5 lysine demethylase family substrate preference and identification of novel substrates.
Hoekstra M; Ridgeway NH; Biggar KK
J Biochem; 2022 Dec; 173(1):31-42. PubMed ID: 36205465
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.
Vazquez-Rodriguez S; Wright M; Rogers CM; Cribbs AP; Velupillai S; Philpott M; Lee H; Dunford JE; Huber KVM; Robers MB; Vasta JD; Thezenas ML; Bonham S; Kessler B; Bennett J; Fedorov O; Raynaud F; Donovan A; Blagg J; Bavetsias V; Oppermann U; Bountra C; Kawamura A; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(2):515-519. PubMed ID: 30431220
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5 C Degraders.
Iida T; Itoh Y; Takahashi Y; Yamashita Y; Kurohara T; Miyake Y; Oba M; Suzuki T
ChemMedChem; 2021 May; 16(10):1609-1618. PubMed ID: 33470543
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
Gilmore SA; Tam D; Cheung TL; Snyder C; Farand J; Dick R; Matles M; Feng JY; Ramirez R; Li L; Yu H; Xu Y; Barnes D; Czerwieniec G; Brendza KM; Appleby TC; Birkus G; Willkom M; Kobayashi T; Paoli E; Labelle M; Boesen T; Tay CH; Delaney WE; Notte GT; Schmitz U; Feierbach B
PLoS One; 2022; 17(12):e0271145. PubMed ID: 36477212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
